Evotec: Milestone as part of its discovery alliance with Boehringer Ingelheim
Advertisement
Evotec AG announced that its research alliance with Boehringer Ingelheim has reached a milestone in September triggering revenues of EUR 4.0 m to Evotec. The milestone was for the transition of an oncology molecule into pre-clinical development.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: 'This is the twentieth milestone achieved as part of our alliance with Boehringer Ingelheim and represents a second oncology compound transitioning into pre-clinical development. I would like to congratulate the teams from both companies on their continuing excellent progress in the collaboration.'
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.